Nowadays, everyone is talking about the importance of our immune systems. Even a person that knows nothing about medicine will definitely know that this is something significant, and that we need to have a strong immune system that will help us fight off certain diseases. How does that happen, though? How does it work, and what makes the difference between a strong and a faulty system, so to speak?
Well, our immune systems actually depend on various signaling molecules, the role of which is to tell our immune cells when to relax, when to act, and generally how to respond in different situations. But, the thing is, this system doesn’t always work properly, which is why we have, well, autoimmune diseases, and inflammatory diseases, which are basically the reflection of certain faults in the system. For instance, in psoriasis, lupus, certain forms of arthritis, and some other diseases as well, some of those signaling molecules can work too hard, so to speak, turning the signals up too high, which results in causing damaging inflammation.
Now, one of the pathways that is responsible for the signaling process is known as TYK2, or tyrosine kinase 2. It has an important role in our overall health, but when it is turned up too high, it can definitely cause some problems. This is why scientists have been trying to develop drugs that could block it when necessary, thus helping in treating inflammatory diseases much better. And, well, Deucravacitinib (BMS-986165) TYK2 Inhibitor has been developed as a possible solution.
As you can see here, it is approved and used for the treatment of psoriasis: https://pmc.ncbi.nlm.nih.gov/articles/PMC10768812/
Given that you are here, you are most likely interested in understanding this drug better, as well as possible in getting it for research purposes, in case you want to study it in more details yourself. Well, this means that you have some important questions, and what we are going to do right now is answer them for you below. So, read on to find out what you need to know, both about the drug in general, and about how to get it for research purposes, if that winds up being an option in the first place.
First, What Is TYK2?
Unsurprisingly, we have to begin with explaining TYK2. After all, not understanding what it is will lead to not understanding what Deucravacitinib (BMS-986165) TYK2 Inhibitor actually does, and how it works. And, since you want to understand the drug, you have to understand the enzyme that it affects. So, let us cut right to the chase and explain this.
Basically, TYK2 is a part of the Janus kinases (JAK) family of enzymes. Those help transmit signals from outside a cell to activate the genes inside the cell, using cytokines and STAT proteins respectively during that process. And, many cytokines that are important in inflammation actually use TYK2 to send their signals.
Why Is Targeting It Important?
Now, why is targeting TYK2 so important, though? Well, because it is somewhat specialized, so to speak, as it isn’t used by all cytokine pathways, inhibiting it actually provides scientists with a chance to dampen the disease-causing inflammation without really affecting and shutting down the entire immune system. We’re talking about targeted therapy here, which further means that you can expect fewer side effects, while still being able to treat certain conditions, such as psoriasis and others. The entire idea is, thus, to block TYK2, which will reduce the overactive immune signaling and ease inflammation, all without too much collateral immunosuppression, which is, as you may understand already, extremely useful.
What Is Deucravacitinib (BMS-986165) TYK2 Inhibitor?
We have now come to the part of understanding the actual drug that you’re here to learn about. Now that you get the pathway I’ve explained above, it’s time to get a better idea about Deucravacitinib (BMS-986165) TYK2 Inhibitor and what it does. And, basically, we are talking about a small molecule medicine that aims at inhibiting TYK2 in a selective, unique way. In other words, it targets this molecule specifically, while not affecting others too much.
This type of selectivity is of crucial importance in targeted therapies. After all, the selectivity results in higher effectiveness and fewer side effects, which is undeniably important in the treatment of any kind of inflammation and autoimmune diseases, because you don’t want to suppress the entire immune system. And, apart from all of this, you should know that this drug is taken orally, which is also a huge benefit for most patients.
Mechanism of Action
Let me now quickly explain how this drug works. We will get into the mechanism of action, but without complicating things too much. In other words, we will keep things simple. So, without any further ado, let us talk about how Deucravacitinib (BMS-986165) TYK2 Inhibitor actually works.
It does not bind to the active site of TYK2, but to an allosteric regulatory domain, thus locking the TYK2 into an inactive state. This type of binding is precisely what makes it so selective, allowing it to avoid interfering with the active kinase domains. And, then, due to this type of inhibition, the activation of STAT proteins and the gene programs that drive inflammation is reduced.
What Are the Advantages?
What are the advantages of this particular drug, though? Well, as you may have guessed it, its selectivity is one of the biggest advantages. But then, the fact that it is dosed orally is also a great benefit. And, due to its broad immunological impact, it is a promising drug for various diseases, not only psoriasis.
How to Get It for Research?
If you’re thinking of getting this drug for your research purposes, then you should undeniably be careful when choosing a supplier. This is because you want to get Deucravacitinib (BMS-986165) TYK2 Inhibitor with a high level of purity, so you need to be careful where you’re buying it. The good news is that you can nowadays find some great suppliers online, and thus check out what they have to offer, and potentially even order the drug from the comfort of your own home.
